These side effects can lead to unforeseen toxicities, especially with multitargeted AXL inhibitors.272,273 Furthermore, the inevitability of relapse in patients with AXL-driven cancers highlights the need for high throughput screening strategies and in-depth understanding of resistance mechanisms. Here, AXL is linked to cancer.